AZD2811

DRUG4 trials

Sponsors

AstraZeneca, Samsung Medical Center

Conditions

Acute Myeloid LeukaemiaAdvanced Solid TumoursSmall Cell Lung CancerSmall-Cell Lung Cancer

Phase 1

A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.

CompletedNCT02579226

AstraZenecaAdvanced Solid Tumours

Start: 2015-10-28End: 2020-04-03Updated: 2020-05-01

Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.

TerminatedNCT03217838

AstraZenecaAcute Myeloid Leukaemia

Start: 2017-07-31End: 2021-03-25Updated: 2022-04-05

Phase 2

AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]

TerminatedNCT03366675

Samsung Medical CenterSmall Cell Lung Cancer

Start: 2017-12-01End: 2018-10-29Updated: 2018-11-27

Study of AZD2811 + Durvalumab in ES-SCLC

Active, not recruitingNCT04745689

AstraZenecaSmall-Cell Lung Cancer

Start: 2021-02-23End: 2026-12-01Updated: 2026-07-06

Related Papers

Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer

British Journal of Cancer2026-04-03

Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours.

2023-03-0428 citations

Abstract P079: The impact of BCL2 expression on sensitivity to the novel Aurora kinase B inhibitor AZD2811 in small cell lung cancer

Molecular Cancer Therapeutics2021-12-01

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

Blood2019-11-135 citations

Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer.

Journal of Clinical Oncology2019-05-2012 citations

A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.

Journal of Clinical Oncology2019-05-206 citations

A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced solid tumors.

Journal of Clinical Oncology2018-05-202 citations

A phase I, open-label, first-time-in-patient dose escalation and expansion study to assess the safety, tolerability, and pharmacokinetics of nanoparticle encapsulated Aurora B kinase inhibitor AZD2811 in patients with advanced solid tumours.

Journal of Clinical Oncology2017-05-209 citations